A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

Conditions

• Mesonephric Gynecologic Cancer

Eligibility Criteria

Sex

FEMALE

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Avutometinib (VS-6766) — DRUG
  3.2 mg PO, twice weekly
• Defactinib — DRUG
  200 mg PO BID for 3 weeks, followed by a 1 week rest period, in each 4-week (28 day) cycle.

Study Details

This study will test if Avutometinib (VS-6766) in combination with Defactinib is an effective treatment for advanced or recurrent mesonephric gynecologic cancer.

Key Dates

Start date

Mar 15, 2023

Status verified

Apr 2026

Primary completion

Mar 31, 2027

Completion

Mar 31, 2027

Study Design

Enrollment

40 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Avutometinib (VS-6766) and Defactinib
  All enrolled patients will be treated with Avutometinib (VS-6766) 3.2 mg PO, twice weekly (e.g. M/Th,Tu/F, or W/Sa) + defactinib 200 mg PO BID for 3 weeks, followed by a 1 week rest period, in each 4-week (28 day) cycle.

Primary Outcome Measure

best overall response [ Time Frame: 2 years ]

Central Contacts

• Rachel Grisham, MD
  646-888-4653
  [email protected]
• Carol Aghajanian, MD
  646-888-4217

Locations (7)

Find similar trials in Basking Ridge, NJ